Literature DB >> 11134251

Oral administration of glomerular basement membrane prevents the development of experimental autoimmune glomerulonephritis in the WKY rat.

John Reynolds1, Charles D Pusey1.   

Abstract

Experimental autoimmune glomerulonephritis (EAG), an animal model of Goodpasture's disease, can be induced in Wistar Kyoto (WKY) rats by a single injection of collagenase-solubilized rat glomerular basement membrane (GBM) in adjuvant. EAG is characterized by circulating and deposited anti-GBM antibodies, accompanied by focal necrotizing glomerulonephritis with crescent formation. The inhibitory effect of orally administered antigens has been reported in various animal models of autoimmunity but not in EAG in the rat. The effects of feeding rat GBM by gavage, at total doses of 0.5, 2.5, or 5 mg, before immunization were examined. A dose-dependent effect was observed on the development of EAG. A dose of 0.5 mg of GBM had no effect on disease, 2.5 mg resulted in a moderate reduction in the severity of nephritis but no change in anti-GBM antibody production, and 5 mg resulted in a marked reduction in circulating and deposited anti-GBM antibodies, albuminuria, deposits of fibrin in the glomeruli, severity of glomerular abnormalities, and numbers of infiltrating T cells and macrophages. Animals that were fed 5 mg of GBM showed a significant reduction in IgG2a but not IgG1, anti-GBM antibody levels, suggesting downregulation of Th1 responses. There was also a dose-dependent reduction in the proliferative responses of splenic T cells from treated animals to GBM antigen in vitro. These results clearly demonstrate that mucosal tolerance can be induced by oral administration of GBM antigen and that this approach is effective in preventing EAG.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11134251     DOI: 10.1681/ASN.V12161

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  9 in total

Review 1.  Cellular aspects of vasculitis--T cell-mediated aspects.

Authors:  M E Griffith; C D Pusey
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Role of T cells and dendritic cells in glomerular immunopathology.

Authors:  Christian Kurts; Felix Heymann; Veronika Lukacs-Kornek; Peter Boor; Jürgen Floege
Journal:  Semin Immunopathol       Date:  2007-10-23       Impact factor: 9.623

3.  Identification of a nephritogenic immunodominant B and T cell epitope in experimental autoimmune glomerulonephritis.

Authors:  J Reynolds; J Haxby; J K Juggapah; D J Evans; C D Pusey
Journal:  Clin Exp Immunol       Date:  2008-11-25       Impact factor: 4.330

Review 4.  Strain differences and the genetic basis of experimental autoimmune anti-glomerular basement membrane glomerulonephritis.

Authors:  John Reynolds
Journal:  Int J Exp Pathol       Date:  2011-02-23       Impact factor: 1.925

5.  Toll-like receptor 9 enhances nephritogenic immunity and glomerular leukocyte recruitment, exacerbating experimental crescentic glomerulonephritis.

Authors:  Shaun A Summers; Oliver M Steinmetz; Joshua D Ooi; Poh-yi Gan; Kim M O'Sullivan; Kumar Visvanathan; Shizuo Akira; A Richard Kitching; Stephen R Holdsworth
Journal:  Am J Pathol       Date:  2010-09-16       Impact factor: 4.307

6.  Mucosal tolerance induced by an immunodominant peptide from rat alpha3(IV)NC1 in established experimental autoimmune glomerulonephritis.

Authors:  John Reynolds; Danielle S Abbott; Julieta Karegli; David J Evans; Charles D Pusey
Journal:  Am J Pathol       Date:  2009-04-30       Impact factor: 4.307

7.  The pathogenicity of T cell epitopes on human Goodpasture antigen and its critical amino acid motif.

Authors:  Shui-Yi Hu; Qiu-Hua Gu; Jia Wang; Miao Wang; Xiao-Yu Jia; Zhao Cui; Ming-Hui Zhao
Journal:  J Cell Mol Med       Date:  2017-03-10       Impact factor: 5.310

Review 8.  Emerging immunotherapies for autoimmune kidney disease.

Authors:  Mary Helen Foster; Jeffrey Robinson Ord
Journal:  Hum Vaccin Immunother       Date:  2019-01-16       Impact factor: 4.526

9.  Novel targets for immunotherapy in glomerulonephritis.

Authors:  Mary H Foster
Journal:  Biologics       Date:  2008-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.